【财经说药】疾病控制率80% VS 股价下跌32%,潜在KRAS G12C抑制剂“BIC”发生了什么?
CN-Healthcare,
财经说药 紧跟上市爆款,分析Ⅲ/Ⅳ临床研究情况 评估市场回报风险 近日,Mirati Therapeutics公布了KRAS G12C抑制剂Adagasib (MRTX849)治疗抗PD-1/L1联合化疗治疗失败的NSCLC患者的最新研究结果,80%的疾病控…
财经说药 紧跟上市爆款,分析Ⅲ/Ⅳ临床研究情况 评估市场回报风险 近日,Mirati Therapeutics公布了KRAS G12C抑制剂Adagasib (MRTX849)治疗抗PD-1/L1联合化疗治疗失败的NSCLC患者的最新研究结果,80%的疾病控…
Sotorasib is for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS G12C Mutation…
Sotorasib is for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS G12C Mutation…
THOUSAND OAKS, Calif., Jan. 29, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its investigational KRAS G12C…